Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods
Rhea-AI Summary
Vanda Pharmaceuticals (Nasdaq: VNDA) criticized the FDA's March 18, 2026 draft guidance on New Approach Methodologies (NAMs), arguing it lacks concrete examples, validation criteria, and citations needed to replace animal tests.
Vanda called for withdrawal and substantial revision, urging clear acceptance pathways, specific validated NAM examples, and collaboration with industry and animal welfare groups.
Positive
- Public push to accelerate NAM adoption and human-relevant testing
- Calls for clearer FDA acceptance pathways for validated NAMs
- Commitment to collaborate with FDA, HHS, scientists, and advocates
Negative
- Draft guidance contains no named NAMs accepted to replace animal tests
- Guidance lacks performance benchmarks and concrete regulatory examples
- Validation requirements described as vague, risking slower NAM adoption
- Limited citations and transparency in authorship reduce scientific clarity
Key Figures
Market Reality Check
Peers on Argus
VNDA slipped -0.47% with low volume while peers showed mixed moves: LXEO appeared in momentum scanners moving -4.84% and MREO up 1.66%, suggesting today’s action is stock-specific rather than a coordinated biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 03 | Regulatory hearing news | Neutral | -4.0% | FDA grants public hearing on proposed refusal of HETLIOZ sNDA. |
| Feb 26 | Conference participation | Neutral | +3.6% | Announcement of corporate presentation at Citizens Life Sciences Conference. |
| Feb 25 | BLA acceptance | Positive | +1.4% | FDA accepts BLA for imsidolimab in generalized pustular psoriasis. |
| Feb 20 | FDA drug approval | Positive | +41.5% | FDA approves BYSANTI™ for bipolar I disorder and schizophrenia. |
| Feb 11 | Earnings results | Negative | -17.6% | Reports 2025 net loss with large tax valuation allowance and 2026 guidance. |
Recent price reactions often align with news tone: strong upside on major approvals, downside on complex regulatory or financial updates, with occasional divergences around procedural or conference news.
Over the last six weeks, VNDA has reported several major updates. FDA approval of BYSANTI™ for bipolar I disorder and schizophrenia on Feb 20 saw a strong +41.49% reaction, while BLA acceptance for imsidolimab in GPP on Feb 25 drew a modest +1.35% move. Earnings on Feb 11—highlighting a $220.5M net loss and a $113.7M tax valuation allowance—coincided with a -17.63% drop. More procedural regulatory items, such as the HETLIOZ® hearing and conference participation, have produced smaller, mixed reactions, framing today’s policy-focused advocacy as part of an ongoing regulatory narrative.
Regulatory & Risk Context
An effective S-3 shelf filed on Feb 12, 2026 allows Vanda to offer up to $200,000,000 of various securities over time for general corporate purposes, though no usage has been recorded to date.
Market Pulse Summary
This announcement underscores Vanda’s role as an advocate for New Approach Methodologies and reduced animal testing, pressing the FDA for clearer, science‑backed guidance. It does not alter product approvals or financial outlook directly but reinforces the company’s regulatory engagement strategy. Investors may watch how the FDA responds to calls for specific NAM examples, validation criteria, and expedited pathways, and whether future guidance meaningfully affects Vanda’s development timelines or nonclinical study requirements.
Key Terms
new approach methodologies medical
in vitro assays medical
AI-generated analysis. Not financial advice.
The FDA's draft guidance aims to support the use of New Approach Methodologies (NAMs)—advanced non-animal tools like in vitro assays, organ-on-chip systems, computational models, and human cell-based platforms—to modernize nonclinical testing and move away from traditional animal models. While Vanda welcomes the FDA's stated commitment to improving human predictivity and ethical standards in drug development, the current draft falls short of delivering the bold, practical reform needed to make this transition a reality.
Vanda has a proven track record of pushing for science-driven change, including legal efforts to challenge FDA requirements for prolonged animal studies—such as nine-month dog toxicity tests—that lack strong scientific justification. These efforts highlight the ethical imperative to minimize animal suffering, particularly in dogs, while advancing more predictive human-relevant methods.
"While we applaud the FDA's direction toward human-centric science, the draft guidance must strike a better balance between regulatory caution and the much-needed scientific reform that modern tools demand," said Mihael H. Polymeropoulos, M.D., President and CEO of Vanda Pharmaceuticals. "Patients deserve faster access to safer drugs, and ethical progress requires us to prioritize methods that better reflect human biology without unnecessary reliance on animals."
Key shortcomings in the draft include:
- Not a single concrete example of any NAM that the FDA currently accepts today to fully replace a required animal test—despite mentioning general categories like in vitro assays for skin sensitization or eye irritation, the document provides zero specific, real-world illustrations, zero named assays or models with acceptance details, zero case studies of waived animal studies, and zero performance benchmarks from actual regulatory submissions or approvals.
- Limited scientific references and practical examples of validated NAMs, leaving developers without clear benchmarks for success.
- Insufficient transparency in authorship and limited citations, falling below the standards expected in credible scientific discourse.
- Vague validation requirements that lack streamlined approval pathways or concrete criteria, potentially creating uncertainty and slowing adoption of innovative tools.
- FDA leadership has repeatedly emphasized the limitations of animal studies in predicting human outcomes. Vanda urges the Agency to fully embrace this perspective by ensuring the final guidance removes barriers rather than introducing new ones.
To help realize the promise of NAMs and accelerate safer, faster drug development, Vanda calls on the FDA to:
- Withdraw the current draft and substantially revise it with stronger scientific grounding.
- Incorporate robust citations to validated NAMs, peer-reviewed studies, and specific, concrete examples of NAMs that have been accepted to replace animal tests, including details on endpoints, performance data, and submission outcomes.
- Provide clear, expedited pathways for regulatory acceptance that prioritize human relevance and evidence-based confidence over outdated precedents.
- Actively collaborate with industry innovators, scientists, and animal welfare groups during the comment period to refine the guidance.
Vanda stands ready to partner with the FDA, HHS, and stakeholders across the ecosystem to advance regulatory policies that harness cutting-edge science, protect patient safety, reduce animal suffering—including in dogs—and align with both ethical and scientific imperatives.
About Vanda Pharmaceuticals
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Various statements in this press release, including, but not limited to, statements regarding future regulatory developments and changes to current policies and practices regarding animal testing, are "forward-looking statements" under the securities laws. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, future FDA or HHS policymaking. Therefore, no assurance can be given that the results or developments anticipated by Vanda will be realized, or even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements in this press release should be evaluated together with the various risks and uncertainties that affect Vanda's business and market, particularly those identified in the "Cautionary Note Regarding Forward-Looking Statements", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's most recent Annual Report on Form 10-K, as updated by Vanda's subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the
All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this press release is provided only as of the date of this press release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-calls-for-stronger-fda-action-to-accelerate-shift-from-animal-testing-to-human-relevant-methods-302719227.html
SOURCE Vanda Pharmaceuticals Inc.
FAQ
What did Vanda (VNDA) say about the FDA's March 18, 2026 NAM guidance?
Why does Vanda (VNDA) want the FDA to withdraw the March 18, 2026 draft guidance?
How could the FDA guidance affect adoption of human-relevant NAMs, per Vanda (VNDA)?
What specific changes does Vanda (VNDA) ask the FDA to make to the NAM guidance?
Will Vanda (VNDA) work with regulators after criticizing the March 18, 2026 guidance?
